{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:51:41Z","timestamp":1791071501924,"version":"4.1.0"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T00:00:00Z","timestamp":1401753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0095184","type":"journal-article","created":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T20:20:56Z","timestamp":1401826856000},"page":"e95184","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2"],"prefix":"10.1371","volume":"9","author":[{"given":"Daruka","family":"Mahadevan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Manziello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Mount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Persky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard I.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,6,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double hit B-cell lymphomas","volume":"117","author":"SM Aukema","year":"2011","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2012.44.4729","article-title":"Growing Importance of <italic>MYC<\/italic>\/<italic>BCL2<\/italic> Immunohistochemistry in Diffuse Large B-Cell Lymphomas","volume":"30","author":"M Pfreundschuh","year":"2012","journal-title":"JCO"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.2012.43.5800","article-title":"Double-Hit Diffuse Large B-Cell Lymphoma","volume":"30","author":"JW Friedberg","year":"2012","journal-title":"JCO"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"KJ Savage","year":"2009","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"NA Johnson","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"TM Green","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.exphem.2011.05.002","article-title":"Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression","volume":"39","author":"N Sasaki","year":"2011","journal-title":"Exp Hematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood-2009-11-251074","article-title":"Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state","volume":"116","author":"J den Hollander","year":"2010","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-11-2413","article-title":"Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma","volume":"18(8)","author":"D Mahadevan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref10","first-page":"434","article-title":"Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res","volume":"37","author":"W Qi","year":"2013"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"JW Friedberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref12","first-page":"881","article-title":"Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol","volume":"81","author":"W Qi","year":"2011"},{"key":"ref13","first-page":"185","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell","volume":"3","author":"A Rosenwald","year":"2003"},{"key":"ref14","first-page":"1937","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med","volume":"346","author":"A Rosenwald","year":"2002"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"S Barrans","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2012-01-406033","article-title":"MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation","volume":"119","author":"W Cuccuini","year":"2012","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"GM Mead","year":"2008","journal-title":"Blood"},{"key":"ref18","first-page":"iv106","article-title":"MYC+ aggressive B-cell lymphomas: Novel therapy of untreated Burkitt lymphoma and MYC+ diffuse large B-cell lymphoma with DA-EPOCH-R","volume":"22","author":"K Dunleavy","year":"2011","journal-title":"Ann Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0095184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T07:58:52Z","timestamp":1540022332000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0095184"}},"subtitle":[],"editor":[{"given":"Irina V.","family":"Lebedeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,3]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0095184","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,3]]}}}